Cargando…

The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma

BACKGROUND: The response rate of immunotherapy via immune checkpoint blockade in hepatocellular carcinoma (HCC) is limited due to multiple immune evasion mechanisms. OX40 is a T cell co-stimulating molecule which suppresses the cancer immune evasion by activating effector T cells (Teffs) and counter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Zhimei, Lin, Liteng, An, Yongcheng, Zhan, Meixiao, Chen, Ye, Cai, Mingyue, Zhu, Xiaojing, Lu, Ligong, Zhu, Kangshun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197594/ https://www.ncbi.nlm.nih.gov/pubmed/34136421 http://dx.doi.org/10.2147/JHC.S301375

Ejemplares similares

Development of OX40 agonists for canine cancer immunotherapy
por: Ruiz, Damien, et al.
Publicado: (2022)

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
por: Linch, Stefanie N., et al.
Publicado: (2015)

Modulating the Tumour Microenvironment by Intratumoural Injection of Pattern Recognition Receptor Agonists
por: Burn, Olivia K., et al.
Publicado: (2020)

Immunologic Effects of Stereotactic Body Radiotherapy in Dogs with Spontaneous Tumors and the Impact of Intratumoral OX40/TLR Agonist Immunotherapy
por: Boss, Mary-Keara, et al.
Publicado: (2022)

Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma
por: Huang, Jingjun, et al.
Publicado: (2021)

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
por: Fromm, George, et al.
Publicado: (2018)

Tumor eradicated by combination of imiquimod and OX40 agonist for in situ vaccination
por: Chu, Yanhong, et al.
Publicado: (2021)

Structural Basis of a Novel Agonistic Anti-OX40 Antibody
por: Zhang, Jing, et al.
Publicado: (2022)

Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist
por: Pieper, Alexander A., et al.
Publicado: (2023)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2020)

Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
por: Salomon, Ran, et al.
Publicado: (2022)

Enhanced systemic tumor suppression by in situ vaccine combining radiation and OX40 agonist with CpG therapy
por: Sun, Zhichen, et al.
Publicado: (2023)

Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma
por: Deng, Shuanglin, et al.
Publicado: (2014)

Intratumoral immunotherapy with the TLR7/8 agonist 3M-052
por: Smirnov, DV, et al.
Publicado: (2013)

Correction to: Development of a novel TLR8 agonist for cancer immunotherapy
por: Wang, Yuxun, et al.
Publicado: (2021)

Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model
por: Alvim, Ricardo G., et al.
Publicado: (2021)

Transarterial chemoembolization combined with sorafenib and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study
por: Huang, Jingjun, et al.
Publicado: (2022)

Andrographolide Ameliorates Liver Fibrosis in Mice: Involvement of TLR4/NF-κB and TGF-β1/Smad2 Signaling Pathways
por: Lin, Liteng, et al.
Publicado: (2018)

Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization
por: Zhang, Di, et al.
Publicado: (2017)

Risk Factors, Patterns, and Long-Term Survival of Recurrence After Radiofrequency Ablation With or Without Transarterial Chemoembolization for Hepatocellular Carcinoma
por: Huang, Jingjun, et al.
Publicado: (2021)

Nanodrug with ROS and pH Dual‐Sensitivity Ameliorates Liver Fibrosis via Multicellular Regulation
por: Lin, Liteng, et al.
Publicado: (2020)

Intraperitoneal injection of class A TLR9 agonist enhances anti–PD-1 immunotherapy in colorectal peritoneal metastases
por: Jiang, Ting, et al.
Publicado: (2022)

Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity
por: Younes, Ahmed I., et al.
Publicado: (2020)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
por: Kim, Tae Won, et al.
Publicado: (2022)

ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
por: Mangsbo, Sara M, et al.
Publicado: (2013)

Deoxyguanosine is a TLR7 agonist
por: Davenne, Tamara, et al.
Publicado: (2019)

Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Huang, Jingjun, et al.
Publicado: (2022)

Local hypoxia is produced at sites of intratumour injection
por: Olive, P L, et al.
Publicado: (2002)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
por: Sun, Jinghua, et al.
Publicado: (2012)

TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects
por: Lu, Hailing
Publicado: (2014)

Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy
por: Rodell, Christopher B., et al.
Publicado: (2019)

The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview
por: Veneziani, Irene, et al.
Publicado: (2022)

Intratumoural injection of the toll-like receptor-2/6 agonist ‘macrophage-activating lipopeptide-2’ in patients with pancreatic carcinoma: a phase I/II trial
por: Schmidt, J, et al.
Publicado: (2007)

Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging
por: Farazi, Michelle, et al.
Publicado: (2014)

Intratumoural administration and tumour tissue targeting of cancer immunotherapies
por: Melero, Ignacio, et al.
Publicado: (2021)

Injection Route and TLR9 Agonist Addition Significantly Impact Heroin Vaccine Efficacy
por: Bremer, Paul T., et al.
Publicado: (2014)

T-cell agonists in cancer immunotherapy
por: Choi, Yeonjoo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_naa8671br2jdbdb5tkl4grhtfd